Sun Pharma’s Organon Bid Sparks Credit Shift: Moody’s Ratings Under Review For Upgrade

This development highlights intensifying merger activity in the global pharmaceutical sector, with Indian giant Sun Pharma eyeing Organon's women's health portfolio to bolster its U.S. presence.

Sun Pharmaceutical Industries, India's largest drugmaker, announced a definitive agreement to acquire Organon & Co., a New Jersey-based specialist in women's health and biosimilars, for approximately $2.7 billion in an all-cash deal. The move comes as Sun Pharma seeks to expand its foothold in high-growth areas like contraception, menopause treatments, and fertility drugs, complementing its existing portfolio.

Key highlights

• Sun Pharma to pay $14.50 per share for Organon, a 13% premium to recent prices
• Acquisition targets Organon's $1.8B annual revenue, mainly from women's health
• Moody's upgrade review reflects improved credit metrics post-deal
• Deal enhances Sun Pharma's biosimilars and branded generics pipeline
  
  

Sources: Moody's Investors Service, Sun Pharma press release, Reuters